STOCK TITAN

Unicycive Q3 2026 net loss widens to $7.0M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Unicycive Therapeutics, Inc. (UNCY) reported third-quarter 2026 research and development expense of $2.2 million, compared with $3.0 million a year earlier. General and administrative expense was $6.6 million, compared with $4.4 million, including $1.4 million related to commercial launch preparation.

Net loss attributable to common stockholders was $(7.0) million, or $(0.25) per share, compared with $(6.0) million, or $(0.33) per share. The company attributed the increased net loss primarily to higher commercial launch expenses. Cash, cash equivalents and marketable securities totaled approximately $59 million as of September 30, 2026, with expected runway beyond 2027, including anticipated increased expenses for an OLC launch should it receive approval.

The FDA accepted Unicycive’s NDA resubmission for oxylanthanum carbonate (OLC), its investigational treatment for hyperphosphatemia in dialysis patients with chronic kidney disease. The PDUFA target action date is March 25, 2027; the company said it is continuing launch preparations alongside FDA review to support a potential launch.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • None.

Negative

  • Moderate pointNet loss attributable to common stockholders increased to $(7.0) million from $(6.0) million.
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Research and development expense $2.2 million Quarter ended September 30, 2026; compared with $3.0 million for the three months ended September 30, 2025.
General and administrative expense $6.6 million Quarter ended September 30, 2026; compared with $4.4 million for the three months ended September 30, 2025.
Other income (expense) $1.8 million Quarter ended September 30, 2026; compared with $1.3 million of income for the three months ended September 30, 2025.
Net loss attributable to common stockholders $(7.0) million Quarter ended September 30, 2026; compared with $(6.0) million for the three months ended September 30, 2025.
Net loss per common share $(0.25) per share Quarter ended September 30, 2026; compared with $(0.33) per share for the three months ended September 30, 2025.
Cash, cash equivalents and marketable securities Approximately $59 million As of September 30, 2026.
Expected cash runway Beyond 2027 Includes anticipated increased expenses related to an OLC launch should it receive approval.
PDUFA target action date March 25, 2027 For FDA review of OLC’s NDA resubmission.
NDA resubmission regulatory
"FDA’s acceptance of our NDA resubmission for OLC"
PDUFA target action date regulatory
"a PDUFA target action date of March 25, 2027"
The PDUFA target action date is the deadline set by the U.S. Food and Drug Administration (FDA) by which it aims to decide whether to approve or reject a new drug application. This date helps investors gauge when a company’s new medication might reach the market, potentially influencing sales and revenue expectations. It acts as a key milestone signaling progress in the drug approval process.
phosphate binding agent medical
"a novel phosphate binding agent"
hyperphosphatemia medical
"treatment of hyperphosphatemia in patients with chronic kidney disease"
An elevated level of phosphate in the blood, often caused by reduced kidney function or certain medications, that can harm bones, blood vessels and organs if untreated. Investors should care because prevalence, safety concerns and regulatory scrutiny around treatments or diagnostics for this condition can drive demand, affect clinical trial outcomes, influence healthcare spending and change a company’s revenue and risk profile—similar to how a common road hazard can change demand for safety products.
orphan drug designation (ODD) regulatory
"granted orphan drug designation (ODD) by the FDA"
Orphan drug designation (ODD) is a regulatory status granted to a medicine intended to treat a rare disease or condition, giving the developer special incentives such as reduced fees, development support, and a period of exclusive market rights. For investors, ODD signals that a product may face less competition, enjoy stronger pricing power, and benefit from lower development costs and regulatory help—similar to receiving a temporary protected license to serve a small but underserved market.
Delayed Graft Function (DGF) medical
"prevention of Delayed Graft Function (DGF)"
Research and development expense $2.2 million Compared with $3.0 million for the three months ended September 30, 2025.
General and administrative expense $6.6 million Compared with $4.4 million for the three months ended September 30, 2025.
Other income (expense) $1.8 million Compared with $1.3 million of income for the three months ended September 30, 2025.
Net loss attributable to common stockholders $(7.0) million Compared with $(6.0) million for the three months ended September 30, 2025.
Net loss per common share $(0.25) per share Compared with $(0.33) per share for the three months ended September 30, 2025.
Cash, cash equivalents and marketable securities Approximately $59 million As of September 30, 2026.
Guidance

Cash runway is expected beyond 2027, including anticipated increased expenses related to the launch of OLC should it receive approval.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was UNCY’s net loss in the third quarter of 2026?

UNCY reported a net loss attributable to common stockholders of $(7.0) million, or $(0.25) per share, for the quarter ended September 30, 2026. The comparable 2025 figures were $(6.0) million and $(0.33) per share. The company attributed the increased net loss primarily to increased commercial launch expenses.

When is the FDA’s target action date for UNCY’s OLC application?

The PDUFA target action date for FDA review of OLC’s NDA resubmission is March 25, 2027. Unicycive said it is advancing launch preparations in parallel with the FDA review to support a potential launch.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001766140 0001766140 2026-11-16 2026-11-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 16, 2026

 

Unicycive Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40582   81-3638692
(State or other jurisdiction   (Commission File Number)   IRS Employer
of incorporation or organization)       Identification No.)

 

4300 El Camino Real, Suite 210

Los Altos, CA 94022

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (650) 351-4495

 

 

(Former name or former address, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class:   Trading Symbol(s)   Name of each exchange on which registered: 
Common Stock   UNCY   Nasdaq Capital Market

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Conditions.

 

On November 16, 2026, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2026 and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

 

The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits.

 

99.1

  Press Release of Unicycive Therapeutics, Inc. dated November 16, 2026.

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: November 16, 2026

 

 

UNICYCIVE THERAPEUTICS, INC.
   
  By: /s/ Shalabh Gupta
    Shalabh Gupta
    Chief Executive Officer

 

2

 

Exhibit 99.1

 

 

Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update

 

-New Drug Application (NDA) for oxylanthanum carbonate (OLC) accepted by the U.S. Food and Drug Administration (FDA), with an assigned Prescription Drug User Fee Act (PDUFA) date of March 25, 2027

 

-As of September 30, 2026, unaudited cash, cash equivalents, and marketable securities totaled $59 million, with expected runway beyond 2027, including the cost of a potential OLC launch

 

MOUNTAIN VIEW, Calif., November 16, 2026 — Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the third quarter ended September 30, 2026, and provided a business update.

 

“We believe that the FDA’s acceptance of our NDA resubmission for OLC marks an important step toward our goal of bringing this much-needed treatment to patients,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “With a PDUFA target action date of March 25, 2027, our focus now is on continuing to advance launch preparations in parallel with the FDA’s review in order to support a potential launch.”

 

Key Highlights & Upcoming Milestones

 

●OLC NDA Resubmission: In October, the Company announced that the FDA has accepted the resubmission of its NDA for OLC and set a PDUFA target action date of March 25, 2027. The NDA was resubmitted following a Complete Response Letter (CRL) received in June 2026, which cited deficiencies previously identified at the original Drug Product (DP) vendor. The June 2026 CRL did not raise concerns regarding clinical efficacy or safety data or request additional data from the Company. The resubmitted NDA remains subject to FDA review.

 

○The NDA resubmission includes CMC data from a new Drug Product manufacturing vendor. The new vendor’s facility was last inspected by the FDA in March 2024 and received “No Action Indicated” status. The Company does not know whether the FDA will decide to conduct a pre-approval inspection of this DP vendor.

 

 

 

 

○The original DP vendor was recently inspected by the FDA. If the FDA finds that its facility complies with current Good Manufacturing Practice (cGMP), the Company plans to align with the FDA on whether that determination could shorten its review timeline and potential approval.

 

●Commercial Readiness: In preparation for the potential launch of OLC, Unicycive continues to advance its commercial readiness initiatives:

 

○Discussions with dialysis organizations as part of the OLC launch planning.

 

○The Company is in active discussions with key commercial leaders with plans to bring them on board in the first quarter of 2027 and, if OLC is approved by the FDA, expects to hire an optimized sales force to target the physician prescriber base.

 

○Unicycive is also focused on optimizing patient access across all reimbursement settings and plans to provide dedicated access and services through its UniSource™ support hub.

 

○On October 28, 2026, the Centers for Medicare & Medicaid Services (CMS) issued its calendar year 2027 End-Stage Renal Disease Prospective Payment System final rule, establishing permanent phosphate binder funding within the dialysis bundled payment through a $12.85 per-treatment addition to the base rate effective January 1, 2027, following the expiration of separate transitional payments for existing binders. CMS also finalized a hyperphosphatemia clinical quality measure beginning with payment year 2029, based on 2027 performance, reinforcing the importance of sustained phosphorus control. Unicycive believes that these changes create favorable commercial launch conditions for OLC, if approved. Subject to FDA approval and CMS confirmation of Transitional Drug Add-on Payment Adjustment (TDAPA) eligibility, OLC could potentially qualify for two years of separate reimbursement at 100% of average sales price while dialysis providers continue to receive the new funding for binders embedded in the base rate, offering potential economic advantage to providers.

 

2

 

 

●TDAPA Eligibility: Unicycive believes OLC meets the criteria for the TDAPA upon FDA approval:

 

○OLC qualified for a 505(b)(2) regulatory path because it contains an active moiety (lanthanum) that was previously approved; however, OLC contains a new active ingredient, oxylanthanum carbonate, that was not previously approved. The Company believes this supports Type 2 NDA classification under the FDA’s Manual of Policies and Procedures 5018.2, NDA Classification Codes.

 

○The determination of OLC’s NDA classification rests solely with the FDA and remains subject to the agency’s determination of NDA classification at the time of approval. The Company believes OLC, if approved, would qualify for TDAPA, subject to meeting applicable CMS requirements.

 

Financial Results for the Quarter Ended September 30, 2026

 

Research and Development (R&D) expense was $2.2 million for the quarter ended September 30, 2026, compared to $3.0 million for the three months ended September 30, 2025. The decrease was primarily driven by a $1.2 million decrease in developments costs, which was partially offset by an increase in non-cash stock-based compensation of $0.5 million.

 

General and Administrative (G&A) expense was $6.6 million for the quarter ended September 30, 2026, compared to $4.4 million for the three months ended September 30, 2025. The increase was primarily driven by a $0.6 million increase in non-cash stock-based compensation as well as an increase of $0.2 million in other labor costs. There was also an increase of $1.4 million related to commercial launch preparation.

 

Other income (expense) was $1.8 million for the quarter ended September 30, 2026, compared to $1.3 million income for the three months ended September 30, 2025, attributed primarily to the change in fair value of the Company’s warrant liability.

 

Net loss attributable to common stockholders, basic and diluted, for the quarter ended September 30, 2026, was $(7.0) million, or $(0.25) per share of common stock, compared to $(6.0) million, or $(0.33) per share of common stock, for the three months ended September 30, 2025. The increased net loss for the quarter ended September 30, 2026, was attributed primarily to an increase in commercial launch expenses.

 

Cash, cash equivalents and marketable securities were approximately $59 million as of September 30, 2026, with expected runway beyond 2027, including anticipated increased expenses related to the launch of OLC should it receive approval.

 

3

 

 

About Unicycive Therapeutics

 

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment, UNI-494, is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.

 

Forward-looking statements

 

 Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Unicycive’s expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; our dependence on third parties for manufacturing; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; market acceptance of our products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

 

Investor Contacts:

 

Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com

 

Media Contact:

 

Unicycive Therapeutics

media@unicycive.com

 

SOURCE: Unicycive Therapeutics, Inc.

 

4

 

Filing Exhibits & Attachments

4 documents

Keep reading